Net clinical benefit of patiromer for acute hyperkalemia: a post-hoc analysis of the reduce trial

NCB captures the clinical benefit of binders, while accounting for the confounding effect of other potassium-lowering agents.

Authors

Institutions

Publication Details

Journal
Annals of Medicine
Published
2025-11-03
DOI
https://doi.org/10.1080/07853890.2025.2581912
Citations
1
Primary Topic
Potassium and Related Disorders
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Net clinical benefit of patiromer for acute hyperkalemia: a post-hoc analysis of the reduce trial

Zubaid Rafique, W. Frank Peacock, Robert McArthur, Jeff Budden
1 citations
Annals of Medicine
Potassium and Related Disorders
1.52
article

Net clinical benefit of patiromer for acute hyperkalemia: a post-hoc analysis of the reduce trial

Zubaid Rafique, W. Frank Peacock, Robert McArthur, Jeff Budden
article en
1 citations

Abstract

NCB captures the clinical benefit of binders, while accounting for the confounding effect of other potassium-lowering agents.

Annals of MedicineVol. 57(1)
Baylor College of Medicine (US), Vifor Pharma (United States) (US)
Openalex Percentile: Top 13%
Potassium and Related Disorders
1.52
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Net clinical benefit of patiromer for acute hyperkalemia: a post-hoc analysis of the reduce trial — Zubaid Rafique, W. Frank Peacock, et al. · Annals of Medicine (2025) | TGRS Research Map | TGRS